AFT Forsyth & Company Inc. Reduces Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

AFT Forsyth & Company Inc. trimmed its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 27.0% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 772 shares of the company’s stock after selling 285 shares during the period. AFT Forsyth & Company Inc.’s holdings in IDEXX Laboratories were worth $319,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the stock. FSA Wealth Management LLC purchased a new position in IDEXX Laboratories during the 3rd quarter worth $25,000. E Fund Management Hong Kong Co. Ltd. grew its position in IDEXX Laboratories by 5,700.0% during the 3rd quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock worth $29,000 after purchasing an additional 57 shares during the last quarter. Retirement Wealth Solutions LLC purchased a new position in IDEXX Laboratories during the 4th quarter worth $31,000. Mowery & Schoenfeld Wealth Management LLC grew its position in IDEXX Laboratories by 750.0% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after purchasing an additional 60 shares during the last quarter. Finally, Ashton Thomas Securities LLC purchased a new position in IDEXX Laboratories during the 3rd quarter worth $37,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Stock Down 1.4 %

IDXX stock opened at $457.35 on Thursday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.03 and a current ratio of 1.31. IDEXX Laboratories, Inc. has a one year low of $398.50 and a one year high of $583.39. The company has a fifty day moving average of $429.67 and a 200-day moving average of $453.23. The stock has a market capitalization of $37.45 billion, a PE ratio of 42.86, a price-to-earnings-growth ratio of 3.47 and a beta of 1.37.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on the stock. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Leerink Partners assumed coverage on shares of IDEXX Laboratories in a research report on Monday, December 2nd. They set an “outperform” rating and a $500.00 price objective on the stock. StockNews.com downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, February 5th. Barclays raised their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 4th. Finally, Piper Sandler raised their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research note on Monday. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average target price of $533.75.

Insider Activity at IDEXX Laboratories

In related news, Director Sophie V. Vandebroek sold 344 shares of the firm’s stock in a transaction dated Wednesday, November 27th. The shares were sold at an average price of $420.44, for a total value of $144,631.36. Following the completion of the sale, the director now owns 905 shares in the company, valued at $380,498.20. This trade represents a 27.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director M Anne Szostak sold 3,000 shares of IDEXX Laboratories stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 13,330 shares of company stock worth $6,161,276 over the last 90 days. Company insiders own 2.11% of the company’s stock.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.